Glyburide Dose Adjustment for Inadequate Glycemic Control

Patient Assessment and Treatment Intensification

• The patient's A1c of 8.7% indicates inadequate glycemic control despite dual therapy with metformin and a sulfonylurea (glyburide), according to the American Diabetes Association, as reported in Diabetes Care 1
• Therapeutic inertia should be avoided when patients are not at their glycemic target, necessitating treatment intensification, as recommended by the American College of Physicians, although this specific reference is from Praxis Medical Insights 2

Treatment Optimization and Monitoring

• Reassess A1c in 3 months after dose adjustment to evaluate treatment effectiveness, as suggested by the National Kidney Foundation 3
• If glycemic control remains inadequate after optimizing glyburide dose, consider adding or switching to a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit, as recommended by the American College of Cardiology and the American Diabetes Association 1, 4

Alternative Therapies and Considerations

• For patients with established cardiovascular disease, consider adding an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit, as recommended by the American College of Cardiology and the American Diabetes Association 1, 4
• The American College of Cardiology recommends considering the cardiovascular and renal benefits of newer agents when making treatment decisions, such as GLP-1 receptor agonists and SGLT2 inhibitors, for patients with inadequate glycemic control 1, 4